BLA 761417 · Beigene
Tevimbra
Tislelizumab-Jsgr · Intravenous
OrphanLast checked: Nov 20, 2026Latest source record: Dec 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Dec 26, 2024
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
747
101 Phase 3, 259 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Tislelizumab" as an intervention, any sponsor and status, largest first.
- The Effect of Serum Ferritin in irAERecruiting
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT06702566 · 1,500 participants (planned) · Start Jul 4, 2024 · Primary completion Jul 16, 2026
Drug: PD-1 and PD-L1 inhibitor; Targeted drugs and 1 more · For: Immune-related Adverse Event; Malignant Solid Tumors; Acute Leukemia and 1 more
Sites: Tianjin, China
- Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction CarcinomaPivotal-lookingCompleted
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT03777657 · 997 participants · Start Dec 13, 2018 · Primary completion Feb 28, 2023
Drug: Tislelizumab; Placebo and 4 more · For: Gastric, or Gastroesophageal Junction Adenocarcinoma
Sites: Sacramento, California; Newnan, Georgia; Columbus, Ohio · 149 sites in all
- A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of ZanubrutinibPivotal-lookingActive, not recruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT04170283 · 955 participants · Start Jan 16, 2020 · Primary completion Dec 31, 2026
Drug: Zanubrutinib; Tislelizumab · For: B-cell Malignancies
Sites: Gilbert, Arizona; Little Rock, Arkansas; Centennial, Colorado · 153 sites in all
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersPivotal-lookingActive, not recruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT05152147 · 920 participants · Start Dec 2, 2021 · Primary completion Jul 15, 2026
Drug: Zanidatamab; Tislelizumab and 5 more · For: Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Pergamino, Argentina · 227 sites in all
- Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingCompleted
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT03358875 · 805 participants · Start Nov 30, 2017 · Primary completion Jul 15, 2021
Drug: Tislelizumab; Docetaxel · For: Non-small Cell Lung Cancer
Sites: Barretos, Brazil; Cachoeiro de Itapemirim, Brazil; Fortaleza, Brazil · 121 sites in all
- ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ AdenocarcinomaPivotal-lookingActive, not recruiting
AskGene Pharma, Inc.Industry
NCT06206733 · 780 participants (planned) · Start Jan 25, 2024 · Primary completion Dec 30, 2026
Drug: ASKB589; Oxaliplatin and 3 more · For: Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma
Sites: Beijing, China
- Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction AdenocarcinomaPivotal-lookingRecruiting
Beijing Biostar Pharmaceuticals Co., Ltd.Industry
NCT06841679 · 778 participants (planned) · Start Aug 28, 2025 · Primary completion Sep 1, 2030
Drug: Utidelone Capsule; Utidelone Capsule and 7 more · For: Gastric or Gastroesophageal Junction Adenocarcinoma
Sites: Hialeah, Florida; Anyang, China; Guangzhou, China · 10 sites in all
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.Pivotal-lookingRecruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT07385703 · 752 participants (planned) · Start Apr 15, 2026 · Primary completion Oct 2028
Drug: LM-302 Injection; Tislelizumab and 2 more · For: Adenocarcinoma
Sites: Hefei, China; Wuhu, China; Beijing, China · 106 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.
Qiu MZ, Oh DY, Kato K, et al. · BMJ 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.
Shitara K, Elimova E, Liu T, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Equivalence Trial
- Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.
Xu J, Kato K, Raymond E, et al. · Lancet Oncol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.
Chen Z, Yang F, Jiang Z, et al. · Lancet 2025 · Clinical Trial, Phase III, Comparative Study
- Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309).
Yang Y, Pan J, Wang H, et al. · Cancer Cell 2023 · Video-Audio Media, Multicenter Study
- Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial.
Yue D, Wang W, Liu H, et al. · Lancet Respir Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: BeOne Medicines (BeiGene)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.